Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase EARLY_PHASE1 2

Status

Completed 49Active not recruiting 28Unknown 18Recruiting 17Terminated 9Not yet recruiting 5Withdrawn 4

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Lymphoid 1

Conditions

Neoplasms 1Lymphoma, Follicular 1Estrogen Receptor Positive 1COVID-19 1Breast Neoplasms 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × palbociclib × Clear all
NCT05371275 2022-11-07

CDK6COV

biotx.ai GmbH

Phase 2 Withdrawn
Lymphoid

COVID-19, Lymphoma, Follicular

NCT04220476 2020-09-21

CIMER

Weill Medical College of Cornell University

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT03377101 2018-08-14

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Estrogen Receptor Positive

NCT03123744 2018-06-21

Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

University of California, San Diego

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡